Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

69.41 +0.21 (+0.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc ADR

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Biotech ETFs To Suffer As US Backs IP Waiver For COVID-19 Vaccines
The Biden administration announced support for the waiver of intellectual property protections for COVID-19 vaccines proposed by South Africa and India. Let’s take a look at ETFs that can suffer from... 
Via Talk Markets
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Could AstraZeneca and Sanofi Win Big in RSV?
The companies have a promising RSV candidate. 
Via The Motley Fool
Calm Markets Day
Despite seriously disappointing April jobless numbers, markets are gaining all the same. 
Via Talk Markets
COVID-19 Vaccine Patent Polarizes The World: What You Need To Know
The COVID-19 pandemic is continuing to rage unabated. Just as countries across the globe were coming online from a protracted lockdown, the second and third wave of the pandemic... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
EMA Safety Committee Reviews Heart Inflammation, Rare Nerve Disorder Reports After Pfizer, AstraZeneca COVID-19 Shots
European Medical Agency (EMA) is reviewing reports of a rare nerve-degenerating disorder in people who received AstraZeneca Plc’s (NASDAQ: AZN)... 
Via Benzinga
Exposures COVID-19
AstraZeneca's Imfinzi, Tremelimumab Combo Boosts Overall Survival In Lung Cancer
A combination of AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy has extended overall survival (OS) when used as... 
Via Benzinga
Why is the EU Suing AstraZeneca?
The EU doesn't think the big drugmaker has held up its end of a supply agreement. 
Via The Motley Fool
Topics Lawsuit
Exposures COVID-19 Financial Legal
Biden Administration Backs Waiving IP Protections For COVID-19 Vaccines, Pharma Industry Rebukes Move
The closely watched issue of patent rights for COVID-19 vaccines garnered headlines again as the Biden administration came out in favor of a proposal at the World Trade... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Single Shot Of AstraZeneca, Pfizer COVID-19 Vaccines Provide 87% Protection, South Korea Study Shows: Reuters
According to real-world data released by South Korea, one dose of COVID-19 vaccines from AstraZeneca Plc (NASDAQ: AZN) and Pfizer Inc (NYSE: PFE) -... 
Via Benzinga
Exposures COVID-19
Should Pfizer and Moderna Be Worried About This New COVID Vaccine Study?
Probably not, but the study could benefit another vaccine maker. 
Via The Motley Fool
Exposures COVID-19
Facebook Sees Paid Subscribers For Workplace Rise 40% But It Remains Far Behind Microsoft's Teams
Facebook Inc (NASDAQ: FB) said Tuesday the number of paid subscribers for its enterprise communication software Workplace has jumped 40% to reach 7 million subscribers,... 
Via Benzinga
Merry Month of May
Today the unhinged markets of Monday went into normal mode as the rest of the world's markets re-opened. 
Via Talk Markets
Stock Wars: AstraZeneca Vs. Pfizer
Benzinga’s Stock Wars series matches up two leaders in a major industry sector, with the goal of letting readers decide which company is ... 
Via Benzinga
Vaxart Stock Plummets On Growing Losses As Investors Eye Covid Pill
Vaxart stock plummeted Monday ahead of a key presentation for its oral Covid vaccine and after the company reported growing first-quarter losses. 
Via Investor's Business Daily
Exposures COVID-19
Vaccine Hesitancy Ticks Down — Here's What That Means For Covid Stocks
Vaccine hesitancy ticked down in May, according to the IBD/TIPP Poll. This could be good news for vaccine stocks Pfizer, Moderna and Johnson & Johnson. 
Via Investor's Business Daily
Novavax Next In List To Start Testing Its COVID-19 Shot In Adolescents
Novavax Inc (NASDAQ: NVAX) has initiated a pediatric expansion of its Phase 3 PREVENT-19 trial for NVX-CoV2373, its COVID-19 vaccine candidate. The additional... 
Via Benzinga
Exposures COVID-19
This Is Why Humira Isn't AbbVie's Biggest Problem Right Now
Two of AbbVie's most important assets could get a lot harder to sell. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
AstraZeneca's Diabetes Drug Farxiga Scores FDA Nod In Kidney Disease
The FDA has approved AstraZeneca plc's (NASDAQ: AZN) Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 inhibitor, to treat chronic kidney disease... 
Via Benzinga
Exposures Product Safety
Moderna Inks Supply Pact Of 500M COVID-19 Vaccine Doses To COVAX Effort Starting Q4
Moderna Inc (NASDAQ: MRNA) has announced an agreement with vaccine promoter Gavi to supply up to 500 million doses of its COVID-19 vaccine to boost the global... 
Via Benzinga
Exposures COVID-19
Who Is — And Will Be — Making Money From COVID-19 Vaccines?
Schroders' Expert John Bowler Analyzes The Pharmaceutical Groups Involved In COVID-19 Drug Development, Emphasizing That Their Efforts Will Be Rewarded In The Future, Despite... 
Via Benzinga
Exposures COVID-19
A Look At The COVID-19 Vaccine Stocks
Based on data as of April 28 from the CDC, over 142 million Americans have received one dose of the COVID-19 vaccine and more than 90 million have been fully vaccinated. This amounts to approximately... 
Via Talk Markets
Exposures COVID-19
Biopharma Stocks Stall After Earnings, Lag Over 52 Weeks
It is hard to forecast with the current choppy setting in the biopharma sector, but assuming that the COVID-19 vaccinations are on track in the U.S., financial results should improve for most large-cap... 
Via Talk Markets
Exposures COVID-19
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid... 
Via Benzinga
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg
Emergent BioSolutions Inc has manufactured over 115 million doses of the drug substance used in the Johnson & Johnson COVID-19 vaccine, 60 million doses of which are in vials and ready to deploy at... 
Via Talk Markets
Exposures COVID-19
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg
Emergent BioSolutions Inc (NYSE: EBS) has manufactured over 115 million doses of drug substance used in the Johnson & Johnson (NYSE: JNJ) COVID-19... 
Via Benzinga
Exposures COVID-19
Novavax Secures Additional $147M From Warp Speed Program For COVID-19 Vaccine
According to an SEC filing, Novavax Inc (NASDAQ: NVAX) has received an additional $147.3M as part of Operation Warp Speed to develop a COVID-19 vaccine dubbed NVX-... 
Via Benzinga
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Why Is AstraZeneca's Stock Trading Higher Today?
AstraZeneca PLC (NASDAQ: AZN) shares are trading higher after the company reported better-than-expected EPS and sales results. AstraZeneca reported first-quarter... 
Via Benzinga
Emergent BioSolutions Hopeful To Restart Vaccine Production, Plans To Submit Response To FDA Within Days
Emergent BioSolutions Inc (NYSE: EBS) said it hopes to respond to U.S. regulators within days on how to resolve the problems at its Baltimore plant, which have forced... 
Via Benzinga
Exposures Product Safety
Why AstraZeneca Stock Is Jumping Today
The company reported better-than-expected first-quarter results. 
Via The Motley Fool
AstraZeneca Stock Jumps On Quarterly Beat, No Thanks To Its Covid Vaccine
AstraZeneca stock popped Friday after the drugmaker beat Wall Street's first-quarter expectations on the back of strong sales for cancer-treating drugs. 
Via Investor's Business Daily
Exposures COVID-19
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.